title: Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease.
abstract: OBJECTIVE
  This study aimed to elucidate whether an antibody against oxidized low density lipoprotein (anti-Ox-LDL) could predict short-term coronary artery atherosclerotic lesion progression.
  
  
  BACKGROUND
  It is still controversial whether higher levels of the anti-Ox-LDL titer are associated with atherosclerotic coronary artery disease.
  
  
  METHODS
  In 52 patients undergoing coronary angioplasty and six-month follow-up angiography, we performed quantitative coronary angiographic analysis of a lesion on a branch away from the intervention site vessel and assessed lesion progression or regression using the Progression-Regression score calculated as the baseline minimal lumen diameter minus the follow-up minimal lumen diameter. The serum anti-Ox-LDL titer was measured using an enzyme-linked immunosorbent assay method just before the initial angiography in all patients.
  
  
  RESULTS
  The anti-Ox-LDL titer was 16.6+/-1.5 AcU/ml in the progression group (Progression-Regression score >0.15 mm; n = 20), which was significantly higher (p < 0.001) than the value of 9.5+/-1.2 in the regression group (< or =-0.15 mm; n = 14) and also higher (p < 0.01) than the value of 11.4+/-1.3 in the no-change group (-0.15 to 0.15 mm; n = 18). The Progression-Regression score was correlated with the antibody titer in all patients (r = 0.56, p < 0.001). Multiple regression analysis showed that the Progression-Regression score was independently correlated with the antibody titer (r = 0.44, p < 0.01) as well as lipoprotein (a) (r = 0.33, p < 0.05).
  
  
  CONCLUSIONS
  Anti-Ox-LDL may be an independent predictor of coronary atherosclerotic lesion progression in the short term.
authors.affiliation: Department of Cardiology, Koshigaya Hospital, Dokkyo University School of Medicine, Saitama, Japan. inouet@dokkyomed.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Inoue
authors.forename: T
authors.initials: T
authors.lastname: Uchida
authors.forename: H
authors.initials: H
authors.lastname: Kamishirado
authors.forename: K
authors.initials: K
authors.lastname: Takayanagi
authors.forename: S
authors.initials: S
authors.lastname: Morooka
mesh_terms: D000906:Antibodies / Q000097:blood*; D003324:Coronary Artery Disease / Q000097:blood / Q000000981:diagnostic imaging* / Q000378:metabolism*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008077:Lipoproteins, LDL / Q000276:immunology* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D011237:Predictive Value of Tests; D011379:Prognosis; D011859:Radiography; D012075:Remission, Spontaneous
chemical_list: D000906:Antibodies; D008077:Lipoproteins, LDL